Yi‐Bo Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yi‐Bo Hou has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jia-Jie Chen
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China
1 shared publication - Kunmei Ji
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences Shenzhen University Medical School, Shenzhen University Shenzhen China
1 shared publication - Li‐Na Zhang
Department of Biochemistry and Molecular Biology, School of Medicine, Shenzhen University, Shenzhen, China
1 shared publication - Yuetong Sun
Biotherapy Centre, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication
Latest Publications
- 4 February 2020
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (12) , 2848-2859
Aurora kinase inhibitor tozasertib suppresses mast cell activation in vitro and in vivo
Background and Purpose Mast cells (MCs) are important in allergic reactions. Here, we assess the anti‐allergic effects of the anti‐cancer drug tozasertib specifically regarding regulatory effects on MCs activation. Experimental Approach Tozasertib effects on MC degranulation was determined by measuring β‐hexosaminidase and histamine release and by assessing morphological changes in RBL‐2H3 and mouse bone marrow‐derived mast cells (BMMCs) stimulated with mouse anti‐dinitrophenyl (DNP)‐immunoglobulin E (IgE)/DNP‐human serum albumin (HSA) or human LAD2 cells activated with phorbol‐12‐myristate 13‐acetate plus calcium ionophore (PMACI). Western blots were performed to detect the expression of molecules involved in NF‐κB, MAPK, and aurora kinase signaling. In vivo anti‐allergic effects of tozasertib were determined in the murine IgE‐mediated passive cutaneous anaphylaxis (PCA) and ovalbumin‐induced active systemic anaphylaxis (ASA) models. Key Results Tozasertib treatment resulted in significantly decreased high‐affinity IgE receptor (FcεRI) or PMACI‐mediated degranulation in RBL‐2H3 cells and in BMMCs or LAD2 cells as evidenced by β‐hexosaminidase or histamine levels. Similarly, tozasertib prevented morphological changes in MCs, such as particle release and F‐actin reorganization. In addition, tozasertib diminished the expression levels of phosphorylated (p)‐NF‐κB p65, p‐Erk1/2, p‐p38 and p‐Aurora A/B markedly, indicating that tozasertib can inhibit the signaling pathway mediating MC activation. Tozasertib attenuated IgE/Ag‐induced PCA dose‐dependently, as evidenced by reduced Evans blue staining. Similarly, tozasertib reduced body temperature levels and serum histamine levels in OVA‐challenged ASA mice. Conclusion and Implications The aurora kinase inhibitor tozasertib suppressed MC activation in vitro and in vivo. Tozasertib may be a potential drug for targeting MC activation to treat allergic diseases or mastocytosis.
- 4 February 2020
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (12) , 2848-2859
Aurora kinase inhibitor tozasertib suppresses mast cell activation in vitro and in vivo
Background and Purpose Mast cells (MCs) are important in allergic reactions. Here, we assess the anti‐allergic effects of the anti‐cancer drug tozasertib specifically regarding regulatory effects on MCs activation. Experimental Approach Tozasertib effects on MC degranulation was determined by measuring β‐hexosaminidase and histamine release and by assessing morphological changes in RBL‐2H3 and mouse bone marrow‐derived mast cells (BMMCs) stimulated with mouse anti‐dinitrophenyl (DNP)‐immunoglobulin E (IgE)/DNP‐human serum albumin (HSA) or human LAD2 cells activated with phorbol‐12‐myristate 13‐acetate plus calcium ionophore (PMACI). Western blots were performed to detect the expression of molecules involved in NF‐κB, MAPK, and aurora kinase signaling. In vivo anti‐allergic effects of tozasertib were determined in the murine IgE‐mediated passive cutaneous anaphylaxis (PCA) and ovalbumin‐induced active systemic anaphylaxis (ASA) models. Key Results Tozasertib treatment resulted in significantly decreased high‐affinity IgE receptor (FcεRI) or PMACI‐mediated degranulation in RBL‐2H3 cells and in BMMCs or LAD2 cells as evidenced by β‐hexosaminidase or histamine levels. Similarly, tozasertib prevented morphological changes in MCs, such as particle release and F‐actin reorganization. In addition, tozasertib diminished the expression levels of phosphorylated (p)‐NF‐κB p65, p‐Erk1/2, p‐p38 and p‐Aurora A/B markedly, indicating that tozasertib can inhibit the signaling pathway mediating MC activation. Tozasertib attenuated IgE/Ag‐induced PCA dose‐dependently, as evidenced by reduced Evans blue staining. Similarly, tozasertib reduced body temperature levels and serum histamine levels in OVA‐challenged ASA mice. Conclusion and Implications The aurora kinase inhibitor tozasertib suppressed MC activation in vitro and in vivo. Tozasertib may be a potential drug for targeting MC activation to treat allergic diseases or mastocytosis.